ERBB2 and hydrops fetalis: The introduction of trastuzumab in therapeutic protocols for ErbB2+ breast cancer has revolutionized the prognosis of patients affected by this disease, but unfortunately this therapy is characterized with a relevant incidence of cardiac dysfunction and HF, especially when associated with anthracyclines.